Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

[1]  Xiao-yan Ma,et al.  Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF , 2024, Cell biology and toxicology.

[2]  Jessica A. Bertout,et al.  Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment , 2024, Frontiers in pharmacology.

[3]  Zhenru Wu,et al.  METTL14/miR‐29c‐3p axis drives aerobic glycolysis to promote triple‐negative breast cancer progression though TRIM9‐mediated PKM2 ubiquitination , 2024, Journal of cellular and molecular medicine.

[4]  Wei Xu,et al.  OTUD3 suppresses the mTORC1 signaling by deubiquitinating KPTN , 2024, Frontiers in pharmacology.

[5]  K. Tsugawa,et al.  Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma , 2024, Breast cancer research and treatment.

[6]  Sai-Yang Zhang,et al.  Annual review of PROTAC degraders as anticancer agents in 2022. , 2024, European journal of medicinal chemistry.

[7]  Resham Bhattacharya,et al.  VEGF signaling: Role in angiogenesis and beyond. , 2024, Biochimica et biophysica acta. Reviews on cancer.

[8]  H. Yue,et al.  Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer , 2023, Journal of ovarian research.

[9]  Yueran Cui,et al.  Biology of Pellino1: a potential therapeutic target for inflammation in diseases and cancers , 2023, Frontiers in immunology.

[10]  Lipeng Pei,et al.  USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway , 2023, Apoptosis : an international journal on programmed cell death.

[11]  Yuan-ming He,et al.  USP7 promotes non‐small‐cell lung cancer cell glycolysis and survival by stabilizing and activating c‐Abl , 2023, Clinical and translational medicine.

[12]  Jizhang Yu,et al.  The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8^+ T-cell immunity , 2023, Cellular & Molecular Immunology.

[13]  Zhentao Yu,et al.  USP4 promotes the proliferation, migration, and invasion of esophageal squamous cell carcinoma by targeting TAK1 , 2023, Cell death & disease.

[14]  Jian Huang,et al.  USP7 reduces the level of nuclear DICER, impairing DNA damage response and promoting cancer progression , 2023, Molecular oncology.

[15]  Lu Liu,et al.  USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1 , 2023, Cell Death & Differentiation.

[16]  Yongbin Lu,et al.  Nickel chloride promotes lung cancer invasion and metastasis by up-regulating the expression of E3 ubiquitin ligase TRIM31 through the IL-6/STAT3 signaling axis. , 2023, Life sciences.

[17]  Wei Wu,et al.  Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma. , 2023, Cancer letters.

[18]  Fang Wang,et al.  A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block “eat-me” signal , 2023, Signal transduction and targeted therapy.

[19]  G. Sethi,et al.  PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer , 2023, Molecular Cancer.

[20]  Yong-jie Zhou,et al.  USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination-mediated degradation , 2023, International journal of oncology.

[21]  Qiyun Tang,et al.  Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer , 2023, Cell & Bioscience.

[22]  Shen-Lin Liu,et al.  circRPS19 affects HK2-mediated aerobic glycolysis and cell viability via the miR-125a-5p/USP7 pathway in gastric cancer , 2023, International journal of oncology.

[23]  J. Ji,et al.  E3 ligase MG53 suppresses tumor growth by degrading cyclin D1 , 2023, Signal transduction and targeted therapy.

[24]  Lei Shi,et al.  FBXO22 inhibits proliferation and metastasis of cervical cancer cells by mediating ubiquitination-dependent degradation of GAK. , 2023, Experimental cell research.

[25]  Tianxin Lin,et al.  UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer , 2023, Cell death & disease.

[26]  Shuqin Jia,et al.  TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance , 2023, Signal transduction and targeted therapy.

[27]  X. Mao,et al.  Ubiquitination is a major modulator for the activation of inflammasomes and pyroptosis. , 2023, Biochimica et biophysica acta. Gene regulatory mechanisms.

[28]  Ezanee Azlina Mohamad Hanif,et al.  Parvimonas micra infection enhances proliferation, wound healing, and inflammation of a colorectal cancer cell line , 2023, Bioscience reports.

[29]  Xianjun Yu,et al.  Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets , 2023, Signal transduction and targeted therapy.

[30]  Mong-Hong Lee,et al.  FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth , 2023, Signal transduction and targeted therapy.

[31]  Q. Yuan,et al.  E3 ubiquitin ligase RNF180 prevents excessive PCDH10 methylation to suppress the proliferation and metastasis of gastric cancer cells by promoting ubiquitination of DNMT1 , 2023, Clinical Epigenetics.

[32]  X. Chen,et al.  Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. , 2023, The Lancet. Respiratory medicine.

[33]  Hao Wang,et al.  Upregulation of USP25 promotes progression of human diffuse large B-cell lymphoma through blocking the ubiquitinated degradation of MDM2. , 2023, Biochemical and biophysical research communications.

[34]  Chang-Woo Lee,et al.  Ubiquitination Links DNA Damage and Repair Signaling to Cancer Metabolism , 2023, International journal of molecular sciences.

[35]  Liang Huang,et al.  A novel protein encoded by circINSIG1 reprograms cholesterol metabolism by promoting the ubiquitin-dependent degradation of INSIG1 in colorectal cancer , 2023, Molecular Cancer.

[36]  Zhenshuang Wang,et al.  De-ubiquitination of SAMHD1 by USP7 promotes DNA damage repair to overcome oncogenic stress and affect chemotherapy sensitivity , 2023, Oncogene.

[37]  Zeyu Zhang,et al.  RNF2 inhibits E-Cadherin transcription to promote hepatocellular carcinoma metastasis via inducing histone mono-ubiquitination , 2023, Cell Death & Disease.

[38]  Mong-Hong Lee,et al.  Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer , 2023, Gut microbes.

[39]  Q. Cao,et al.  Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 Expression , 2023, Aging and disease.

[40]  G. Hu,et al.  MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation , 2023, Cell Discovery.

[41]  Lei Ding,et al.  Trigred motif 36 regulates neuroendocrine differentiation of prostate cancer via HK2 ubiquitination and GPx4 deficiency , 2023, Cancer science.

[42]  Z. Zeng,et al.  PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination , 2023, The Journal of clinical investigation.

[43]  Daming Zuo,et al.  HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway , 2023, Journal of Experimental & Clinical Cancer Research.

[44]  R. Doebele,et al.  A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  GuanNing Shang,et al.  The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy , 2023, Frontiers in Immunology.

[46]  C. Glass,et al.  Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis , 2023, Nature Communications.

[47]  Xin Jin,et al.  SETDB1 modulates degradation of phosphorylated RB and anti-cancer efficacy of CDK4/6 inhibitors. , 2023, Cancer research.

[48]  Chuan Wang,et al.  USP48 stabilizes gasdermin E to promote pyroptosis in cancer. , 2023, Cancer research.

[49]  Yufeng Yuan,et al.  METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression , 2023, Cancer communications.

[50]  Chao Yu,et al.  RNF7 Facilitated the Tumorigenesis of Pancreatic Cancer by Activating PI3K/Akt Signaling Pathway , 2023, Oxidative medicine and cellular longevity.

[51]  N. Magné,et al.  Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. , 2023, European journal of cancer.

[52]  S. Fan,et al.  RNF126‐Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple‐Negative Breast Cancer to Radiotherapy , 2022, Advanced science.

[53]  Xiaozhen Zhang,et al.  Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer , 2022, Cell Death & Differentiation.

[54]  Ruhua Zhang,et al.  Targeting the Lysosomal Degradation of Rab22a‐NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis , 2022, Advanced science.

[55]  Xia Li,et al.  Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma , 2022, Cell Death & Differentiation.

[56]  Haojie Huang,et al.  Deregulation of SPOP in cancer. , 2022, Cancer research.

[57]  Xianjun Yu,et al.  Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research , 2022, Journal of hematology & oncology.

[58]  T. Liang,et al.  Identification of a class of potent USP25/28 inhibitors with broad-spectrum anti-cancer activity , 2022, Signal transduction and targeted therapy.

[59]  Jian Zhu,et al.  RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling , 2022, Cell Death & Disease.

[60]  Yan Zhou,et al.  RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer , 2022, Journal of Experimental & Clinical Cancer Research.

[61]  K. Venkatakrishnan,et al.  Effect of Pevonedistat, an Investigational NEDD8‐Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors , 2022, Clinical pharmacology in drug development.

[62]  L. Qin,et al.  CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1 , 2022, Oncogene.

[63]  E. Keung,et al.  Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma , 2022, Frontiers in Oncology.

[64]  T. Stiewe,et al.  Peptide-mediated inhibition of the transcriptional regulator Elongin BC induces apoptosis in cancer cells , 2022, bioRxiv.

[65]  M. Konopleva,et al.  Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial , 2022, Blood.

[66]  H. Ohno,et al.  Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia , 2022, International Journal of Hematology.

[67]  M. Oren,et al.  Drugging p53 in cancer: one protein, many targets , 2022, Nature Reviews Drug Discovery.

[68]  Q. Lv,et al.  TRIM35 ubiquitination regulates the expression of PKM2 tetramer and dimer and affects the malignant behaviour of breast cancer by regulating the Warburg effect , 2022, International journal of oncology.

[69]  Xiaoping Zhou,et al.  Long non‐coding RNA VAL facilitates PKM2 enzymatic activity to promote glycolysis and malignancy of gastric cancer , 2022, Clinical and translational medicine.

[70]  C. Zhang,et al.  USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer , 2022, Nature Communications.

[71]  Yanchang Li,et al.  [Progress in atypical ubiquitination via K6-linkages]. , 2022, Sheng wu gong cheng xue bao = Chinese journal of biotechnology.

[72]  Zhan Wang,et al.  Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer , 2022, Journal of Translational Medicine.

[73]  Qihong Huang,et al.  Cav2.2-NFAT2-USP43 axis promotes invadopodia formation and breast cancer metastasis through cortactin stabilization , 2022, Cell Death & Disease.

[74]  Quanjiao Chen,et al.  N6-methyladenosine modification of circ_0003215 suppresses the pentose phosphate pathway and malignancy of colorectal cancer through the miR-663b/DLG4/G6PD axis , 2022, Cell Death & Disease.

[75]  Xiang Chen,et al.  Targeting Ferroptosis by Ubiquitin System Enzymes: A Potential Therapeutic Strategy in Cancer , 2022, International journal of biological sciences.

[76]  J. Zhang,et al.  DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2 , 2022, Signal Transduction and Targeted Therapy.

[77]  Xiaoxue Zhou,et al.  Role of pyroptosis in inflammation and cancer , 2022, Cellular & Molecular Immunology.

[78]  K. Venkatakrishnan,et al.  Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors , 2022, Investigational New Drugs.

[79]  X. Chen,et al.  Long Non-coding RNA UCA1a Promotes Proliferation via PKM2 in Cervical Cancer , 2022, Reproductive Sciences.

[80]  Nobuko Matsushita,et al.  DNA Damage Response Regulation by Histone Ubiquitination , 2022, International journal of molecular sciences.

[81]  Jie Han,et al.  Emerging Roles of Non-proteolytic Ubiquitination in Tumorigenesis , 2022, Frontiers in Cell and Developmental Biology.

[82]  H. Ding,et al.  Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERα Expression. , 2022, Journal of medicinal chemistry.

[83]  Mingxi Gan,et al.  Deacetylation of Glutaminase by HDAC4 contributes to Lung Cancer Tumorigenesis , 2022, International journal of biological sciences.

[84]  X. Xiang,et al.  Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment. , 2022, Cytokine & growth factor reviews.

[85]  R. Nanda,et al.  ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study. , 2022, Journal of Clinical Oncology.

[86]  R. Sullivan,et al.  Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study , 2022, Investigational New Drugs.

[87]  D. Faller,et al.  Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine , 2022, Journal of Hematology & Oncology.

[88]  G. Freeman,et al.  USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy , 2022, Nature Communications.

[89]  K. Engeland.  Cell cycle regulation: p53-p21-RB signaling , 2022, Cell Death & Differentiation.

[90]  Y. Hu,et al.  Programmed Cell Death Tunes Tumor Immunity , 2022, Frontiers in Immunology.

[91]  A. Medvedev,et al.  Atypical Ubiquitination and Parkinson’s Disease , 2022, International journal of molecular sciences.

[92]  Xiang Li,et al.  RAD6 Positively Affects Tumorigenesis of Esophageal Squamous Cell Carcinoma by Regulating Histone Ubiquitination of CCNB1 , 2022, Biological procedures online.

[93]  Yuting Sheng,et al.  UBE2B promotes ovarian cancer growth via promoting RAD18 mediated ZMYM2 monoubiquitination and stabilization , 2022, Bioengineered.

[94]  Siyuan Zheng,et al.  M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression. , 2022, Cancer research.

[95]  C. Denkert,et al.  How VEGF-A and its splice variants affect breast cancer development – clinical implications , 2022, Cellular Oncology.

[96]  Pengyun Qiao,et al.  Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis , 2022, Cell Death & Differentiation.

[97]  S. Ren,et al.  OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR , 2022, Communications biology.

[98]  Yu Cao,et al.  Mcl‐1 inhibition overcomes BET inhibitor resistance induced by low FBW7 expression in breast cancer , 2022, Journal of cellular and molecular medicine.

[99]  Jun Lu,et al.  EZH2–CCF–cGAS Axis Promotes Breast Cancer Metastasis , 2022, International journal of molecular sciences.

[100]  Y. Ando,et al.  A phase I study of LCL161, a novel oral pan‐inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors , 2022, Asia-Pacific journal of clinical oncology.

[101]  J. Weber,et al.  It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy , 2022, Frontiers in Cell and Developmental Biology.

[102]  Xin Jin,et al.  A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression , 2022, Journal of experimental & clinical cancer research : CR.

[103]  Xiao-jing Yang,et al.  USP44 regulates irradiation-induced DNA double-strand break repair and suppresses tumorigenesis in nasopharyngeal carcinoma , 2022, Nature Communications.

[104]  Xiao-jing Yang,et al.  USP44 regulates irradiation-induced DNA double-strand break repair and suppresses tumorigenesis in nasopharyngeal carcinoma , 2022, Nature communications.

[105]  C. Heldin,et al.  Deubiquitinating enzymes USP4 and USP17 finetune the trafficking of PDGFRβ and affect PDGF-BB-induced STAT3 signalling , 2022, Cellular and Molecular Life Sciences.

[106]  Xi Luo,et al.  FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation , 2022, Cellular and Molecular Life Sciences.

[107]  S. Oh,et al.  Human gut-microbiome-derived propionate coordinates proteasomal degradation via HECTD2 upregulation to target EHMT2 in colorectal cancer , 2022, The ISME Journal.

[108]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[109]  D. Longley,et al.  The role of Ubiquitination in Apoptosis and Necroptosis , 2021, Cell Death & Differentiation.

[110]  J. Esteve,et al.  Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  B. Jung,et al.  USP14 Regulates Cancer Cell Growth in a Fatty Acid Synthase-Independent Manner , 2021, International Journal of Molecular Sciences.

[112]  Jong-Ho Cha,et al.  Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges , 2021, Cells.

[113]  G. Stark,et al.  The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage , 2021, Proceedings of the National Academy of Sciences.

[114]  Zongfu Pan,et al.  Overview of PROTACs targeting the estrogen receptor: Achievements for biological and drug discovery. , 2021, Current medicinal chemistry.

[115]  Shouzhen Chen,et al.  FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance , 2021, Cancer Research.

[116]  A. Berger,et al.  TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data , 2021, Blood.

[117]  P. Convertini,et al.  Mitochondria-Mediated Apoptosis of HCC Cells Triggered by Knockdown of Glutamate Dehydrogenase 1: Perspective for Its Inhibition through Quercetin and Permethylated Anigopreissin A , 2021, Biomedicines.

[118]  Xiaofeng Zheng,et al.  Deubiquitinase OTUB2 exacerbates the progression of colorectal cancer by promoting PKM2 activity and glycolysis , 2021, Oncogene.

[119]  S. Choksi,et al.  Necroptosis and tumor progression. , 2021, Trends in cancer.

[120]  Z. Dong,et al.  Targeting integrin αvβ3 with indomethacin inhibits patient‐derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma , 2021, Clinical and translational medicine.

[121]  T. V. Nguyen.  USP15 antagonizes CRL4CRBN-mediated ubiquitylation of glutamine synthetase and neosubstrates , 2021, Proceedings of the National Academy of Sciences.

[122]  G. Giaccone,et al.  Molecular predictors of response to pembrolizumab in thymic carcinoma , 2021, Cell reports. Medicine.

[123]  J. Perentesis,et al.  The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia , 2021, Leukemia.

[124]  S. Burley,et al.  mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma , 2021, Cancer Research.

[125]  Yichao Zheng,et al.  Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy. , 2021, Bioorganic chemistry.

[126]  Heshui Wu,et al.  Deubiquitination of FBP1 by USP7 blocks FBP1–DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors , 2021, Molecular oncology.

[127]  Fangfang Bi,et al.  Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2 , 2021, Molecular oncology.

[128]  G. Zhuang,et al.  USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade , 2021, Nature Communications.

[129]  Wenyi Wei,et al.  SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions , 2021, Molecular Cancer.

[130]  M. Wei,et al.  MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9 , 2021, International journal of biological sciences.

[131]  Joong-Sub Choi,et al.  Telomere shortening and expression of TRF1 and TRF2 in uterine leiomyoma. , 2021, Molecular medicine reports.

[132]  Dan Chen,et al.  E3 ubiquitin ligases: styles, structures and functions , 2021, Molecular Biomedicine.

[133]  B. He,et al.  Inhibition of USP11 sensitizes gastric cancer to chemotherapy via suppressing RhoA and Ras-mediated signaling pathways. , 2021, Clinics and research in hepatology and gastroenterology.

[134]  G. Naik,et al.  Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 , 2021, Clinical Cancer Research.

[135]  Hua Yu,et al.  Cytosolic GDH1 degradation restricts protein synthesis to sustain tumor cell survival following amino acid deprivation , 2021, The EMBO journal.

[136]  Wendong Li,et al.  Abstract 2435: Transcription Factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expression , 2021, Molecular and Cellular Biology/Genetics.

[137]  J. Blay,et al.  Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors , 2021, Investigational New Drugs.

[138]  G. Demetri,et al.  Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies , 2021, British Journal of Cancer.

[139]  Y. Xiong,et al.  Advancing targeted protein degradation for cancer therapy , 2021, Nature Reviews Cancer.

[140]  J. Kato,et al.  Stabilization of fatty acid synthesis enzyme acetyl-CoA carboxylase 1 suppresses acute myeloid leukemia development. , 2021, The Journal of clinical investigation.

[141]  Mark Lee,et al.  Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan , 2021, Clinical and translational science.

[142]  Zev A. Binder,et al.  Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy , 2021, Frontiers in Oncology.

[143]  R. Deng,et al.  CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression , 2021, Autophagy.

[144]  Yu Pan,et al.  TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance , 2021, Cellular and molecular gastroenterology and hepatology.

[145]  Dajun Yang,et al.  MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models , 2021, Cell death discovery.

[146]  H. Liang,et al.  DNMT3A-mediated silence in ADAMTS9 expression is restored by RNF180 to inhibit viability and motility in gastric cancer cells , 2021, Cell Death & Disease.

[147]  C. Prives,et al.  The roles and regulation of MDM2 and MDMX: it is not just about p53 , 2021, Genes & development.

[148]  Qiaojun He,et al.  Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy. , 2021, Pharmacological research.

[149]  Jindan Yu,et al.  Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer , 2021, Science Advances.

[150]  E. Latz,et al.  Necroptosis, pyroptosis and apoptosis: an intricate game of cell death , 2021, Cellular & Molecular Immunology.

[151]  Jinbao Liu,et al.  The deubiquitinating enzyme USP15 stabilizes ERα and promotes breast cancer progression , 2021, Cell Death & Disease.

[152]  Chihao Zhang,et al.  TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination , 2021, Frontiers in Cell and Developmental Biology.

[153]  Fang Wang,et al.  Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression , 2021, Advanced science.

[154]  C. K. Schmidt,et al.  E2 Enzymes in Genome Stability: Pulling the Strings Behind the Scenes. , 2021, Trends in cell biology.

[155]  Shanshan Wang,et al.  FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2 , 2021, Molecular cancer.

[156]  S. Kang,et al.  CHIP and BAP1 Act in Concert to Regulate INO80 Ubiquitination and Stability for DNA Replication , 2021, Molecules and cells.

[157]  Shou-Jiang Gao,et al.  RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation , 2021, Nature Communications.

[158]  Ruhua Zhang,et al.  Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes , 2021, Signal Transduction and Targeted Therapy.

[159]  A. McIntyre,et al.  Therapeutic Potential of Pharmacological Targeting NLRP3 Inflammasome Complex in Cancer , 2021, Frontiers in Immunology.

[160]  J. Qin,et al.  Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2Prame complex , 2021, Cell Death & Differentiation.

[161]  D. Faller,et al.  Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML , 2021, Leukemia.

[162]  Yongmei Song,et al.  Transcriptional dysregulation of TRIM29 promotes colorectal cancer carcinogenesis via pyruvate kinase-mediated glucose metabolism , 2021, Aging.

[163]  Shitao Li,et al.  The Role of Ubiquitination in NF-κB Signaling during Virus Infection , 2021, Viruses.

[164]  A. San Martin,et al.  Metabolic adaptation in hypoxia and cancer. , 2021, Cancer letters.

[165]  I. Wertz,et al.  Ubiquitination in the regulation of inflammatory cell death and cancer , 2021, Cell Death & Differentiation.

[166]  Shuang Hu,et al.  Emerging role of RNF2 in cancer: From bench to bedside , 2021, Journal of cellular physiology.

[167]  W. Barcellini,et al.  Bortezomib in autoimmune hemolytic anemia and beyond , 2021, Therapeutic Advances in Hematology.

[168]  M. Raftery,et al.  HCMV-Mediated Interference of Bortezomib-Induced Apoptosis in Colon Carcinoma Cell Line Caco-2 , 2021, Viruses.

[169]  Shota Yamamoto,et al.  Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy , 2021, International journal of molecular sciences.

[170]  Jun Huang,et al.  MRN complex is an essential effector of DNA damage repair , 2021, Journal of Zhejiang University-SCIENCE B.

[171]  V. Gorgoulis,et al.  Non-Canonical Functions of the ARF Tumor Suppressor in Development and Tumorigenesis , 2021, Biomolecules.

[172]  S. Fulda,et al.  USP22 controls necroptosis by regulating receptor‐interacting protein kinase 3 ubiquitination , 2020, EMBO reports.

[173]  J. K. Yun,et al.  Sequential ubiquitination of p53 by TRIM28, RLIM, and MDM2 in lung tumorigenesis , 2020, Cell Death & Differentiation.

[174]  S. Markowitz,et al.  Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. , 2020, Gastroenterology.

[175]  G. Kroemer,et al.  Ferroptosis: molecular mechanisms and health implications , 2020, Cell Research.

[176]  W. Pierceall,et al.  Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆. , 2020, Leukemia research.

[177]  P. Kleiblova,et al.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate , 2020, Cells.

[178]  Sung-Liang Yu,et al.  PCDH10 exerts tumor-suppressor functions through modulation of EGFR/AKT axis in colorectal cancer. , 2020, Cancer letters.

[179]  Z. Dong,et al.  Honokiol Inhibits Melanoma Growth by Targeting Keratin 18 in vitro and in vivo , 2020, Frontiers in Cell and Developmental Biology.

[180]  D. Longley,et al.  Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer , 2020, Molecular Cancer Therapeutics.

[181]  J. Dick,et al.  CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells. , 2020, Blood.

[182]  R. Deng,et al.  BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN , 2020, Molecular oncology.

[183]  T. Waldmann,et al.  Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma , 2020, Proceedings of the National Academy of Sciences.

[184]  E. Maspero,et al.  USP25 Regulates EGFR Fate by Modulating EGF-Induced Ubiquitylation Dynamics , 2020, Biomolecules.

[185]  Xiaokun Zhao,et al.  USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway , 2020, International journal of biological sciences.

[186]  Q. Dong,et al.  Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies , 2020, Frontiers in Oncology.

[187]  Zhiyong Guo,et al.  USP19 suppresses inflammation and promotes M2-like macrophage polarization by manipulating NLRP3 function via autophagy , 2020, Cellular & Molecular Immunology.

[188]  K. Venkatakrishnan,et al.  Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors , 2020, Investigational New Drugs.

[189]  Li Liu,et al.  UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation , 2020, Journal of Experimental & Clinical Cancer Research.

[190]  Zhiguo Wang,et al.  FBW7 Mediates Senescence and Pulmonary Fibrosis through Telomere Uncapping. , 2020, Cell metabolism.

[191]  F. Esposito,et al.  TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas , 2020, Molecular oncology.

[192]  Qing Yang,et al.  The role of ubiquitination and deubiquitination in cancer metabolism , 2020, Molecular Cancer.

[193]  L. Zhuang,et al.  Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy , 2020, Protein & Cell.

[194]  F. McKeon,et al.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. , 2020, Cancer letters.

[195]  Hao Wu,et al.  Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development. , 2020, The Journal of clinical investigation.

[196]  Bo Xu,et al.  Rho‐associated protein kinase‐dependent moesin phosphorylation is required for PD‐L1 stabilization in breast cancer , 2020, Molecular oncology.

[197]  Liwu Fu,et al.  Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells , 2020, Molecular cancer.

[198]  A. Harris,et al.  HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. , 2020, The Journal of clinical investigation.

[199]  Ping-Chih Ho,et al.  Lactate modulation of immune responses in inflammatory versus tumour microenvironments , 2020, Nature Reviews Immunology.

[200]  F. Thorsen,et al.  TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα , 2020, Cell Death & Differentiation.

[201]  B. Liao,et al.  Abstract 6367: KPG-818, a novel cereblon modulator, inhibits hematological malignancies in preclinical models , 2020 .

[202]  Xianjun Yu,et al.  Ferroptosis, necroptosis, and pyroptosis in anticancer immunity , 2020, Journal of Hematology & Oncology.

[203]  Jiong Wu,et al.  ABL1-dependent OTULIN phosphorylation promotes genotoxic Wnt/β-catenin activation to enhance drug resistance in breast cancers , 2020, Nature Communications.

[204]  C. Crews,et al.  PROTACs: An Emerging Therapeutic Modality in Precision Medicine. , 2020, Cell chemical biology.

[205]  D. Oh,et al.  Post-Translational Regulation of ARF: Perspective in Cancer , 2020, Biomolecules.

[206]  Li-na Zhou,et al.  USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma , 2020, Nature Communications.

[207]  S. Fan,et al.  The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells , 2020, Cell Communication and Signaling.

[208]  M. Konopleva,et al.  MDM2 inhibition: an important step forward in cancer therapy , 2020, Leukemia.

[209]  Z. Shao,et al.  Aspeterreurone A, a Cytotoxic Dihydrobenzofuran-Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus Aspergillus terreus CC-S06-18. , 2020, Journal of natural products.

[210]  Ainsley Mike Antao,et al.  Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics , 2020, Cancers.

[211]  I. Taylor,et al.  First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI). , 2020 .

[212]  D. Rasco,et al.  Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors. , 2020 .

[213]  Wenbin Liu,et al.  Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis , 2020, Cell Death & Disease.

[214]  H. Kiyonari,et al.  LUBAC accelerates B-cell lymphomagenesis by conferring B cells resistance to genotoxic stress. , 2020, Blood.

[215]  T. Waldmann,et al.  A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models , 2020, Clinical Cancer Research.

[216]  Guoqiang Chen,et al.  FBXO22 degrades nuclear PTEN to promote tumorigenesis , 2020, Nature Communications.

[217]  S. Davies,et al.  OTULIN protects the liver against cell death, inflammation, fibrosis, and cancer , 2020, Cell Death & Differentiation.

[218]  Liu Lianxin,et al.  Ubiquitin-specific protease 22 is associated with poor prognosis in neuroblastoma. , 2020, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[219]  Tao Tao,et al.  mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges , 2020, Cell & Bioscience.

[220]  Xingbo Zhao,et al.  TRIM22 inhibits endometrial cancer progression through the NOD2/NF-kB signaling pathway and confers a favorable prognosis , 2020, International journal of oncology.

[221]  P. Venugopal,et al.  Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma , 2020, Investigational New Drugs.

[222]  Wenyi Wei,et al.  The role of ubiquitination in tumorigenesis and targeted drug discovery , 2020, Signal Transduction and Targeted Therapy.

[223]  X. Che,et al.  miR-1323 Promotes Cell Migration in Lung Adenocarcinoma by Targeting Cbl-b and Is an Early Prognostic Biomarker , 2020, Frontiers in Oncology.

[224]  Yanju Ma,et al.  β-Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323/Cbl-b/EGFR pathway. , 2020, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[225]  B. Higgins,et al.  Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia , 2020, Investigational New Drugs.

[226]  W. Kolch,et al.  Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity , 2020, International journal of molecular sciences.

[227]  Murugesan V. S. Rajaram,et al.  Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia , 2020, The Journal of experimental medicine.

[228]  Junwei Wang,et al.  BICP0 Negatively Regulates TRAF6-Mediated NF-κB and Interferon Activation by Promoting K48-Linked Polyubiquitination of TRAF6 , 2020, Frontiers in Microbiology.

[229]  L. Fricker.  Proteasome Inhibitor Drugs. , 2020, Annual review of pharmacology and toxicology.

[230]  Jing Yang,et al.  USP15 potentiates NF-κB activation by differentially stabilizing TAB2 and TAB3. , 2020, The FEBS journal.

[231]  B. Stanger,et al.  Tumor Cell–Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer , 2019, Cancer Immunology Research.

[232]  C. Qin,et al.  The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein , 2019, Cell Death & Differentiation.

[233]  Dajun Yang,et al.  MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment , 2019, Journal of Immunotherapy for Cancer.

[234]  Q. Dou,et al.  Deubiquitination and stabilization of Estrogen Receptor α by Ubiquitin-Specific Protease 7 promotes breast tumorigenesis. , 2019, Cancer letters.

[235]  Haiyang Xie,et al.  USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation , 2019, Gut.

[236]  Xi Wu,et al.  Pyroptosis: A new frontier in cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[237]  A. Dimberg,et al.  Tumor angiogenesis: causes, consequences, challenges and opportunities , 2019, Cellular and Molecular Life Sciences.

[238]  D. Oh,et al.  ATM in DNA repair in cancer. , 2019, Pharmacology & therapeutics.

[239]  A. Ribas,et al.  Tumour-intrinsic resistance to immune checkpoint blockade , 2019, Nature Reviews Immunology.

[240]  Matthieu Schapira,et al.  Targeted protein degradation: expanding the toolbox , 2019, Nature Reviews Drug Discovery.

[241]  L. Ouyang,et al.  The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy. , 2019, European journal of medicinal chemistry.

[242]  Xing Huang,et al.  USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity , 2019, Cancer Immunology Research.

[243]  J. Blay,et al.  Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma , 2019, Investigational New Drugs.

[244]  Ping-Tzu Chen,et al.  Deubiquitylatinase inhibitor b-AP15 induces c-Myc-Noxa-mediated apoptosis in esophageal squamous cell carcinoma , 2019, Apoptosis.

[245]  E. Rasmussen,et al.  Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. , 2019, Blood advances.

[246]  Wenjing Zhang,et al.  Ubiquitin-specific protease 3 promotes cell migration and invasion by interacting with and deubiquitinating SUZ12 in gastric cancer , 2019, Journal of Experimental & Clinical Cancer Research.

[247]  P. He,et al.  FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth , 2019, Cell Death & Disease.

[248]  Zhou Jiang,et al.  DNA damage-induced activation of ATM promotes β-TRCP-mediated ARID1A ubiquitination and destruction in gastric cancer cells , 2019, Cancer Cell International.

[249]  K. Venkatakrishnan,et al.  Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours , 2019, British journal of clinical pharmacology.

[250]  Soo Young Lee,et al.  C-Cbl negatively regulates TRAF6-mediated NF-κB activation by promoting K48-linked polyubiquitination of TRAF6 , 2019, Cellular & Molecular Biology Letters.

[251]  J. Zhi,et al.  A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors , 2019, Cancer Chemotherapy and Pharmacology.

[252]  B. Stanger,et al.  Cellular Plasticity in Cancer. , 2019, Cancer discovery.

[253]  Jeong-Min Park,et al.  Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks , 2019, Nature Communications.

[254]  A. Jeyasekharan,et al.  Molecular pathogenic pathways in extranodal NK/T cell lymphoma , 2019, Journal of Hematology & Oncology.

[255]  A. Alimonti,et al.  Cellular Senescence: Aging, Cancer, and Injury. , 2019, Physiological reviews.

[256]  Jeremy D. Wong,et al.  Ubiquitin receptors are required for substrate-mediated activation of the proteasome’s unfolding ability , 2019, Scientific Reports.

[257]  Hua Li,et al.  FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation , 2019, Nature Communications.

[258]  Hai-rong Chen,et al.  Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway , 2019, Investigational New Drugs.

[259]  B. Helmink,et al.  The microbiome, cancer, and cancer therapy , 2019, Nature Medicine.

[260]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[261]  N. Ferrara,et al.  VEGF in Signaling and Disease: Beyond Discovery and Development , 2019, Cell.

[262]  Jie Gu,et al.  Ubiquitin-protein ligase E3C maintains non-small-cell lung cancer stemness by targeting AHNAK-p53 complex. , 2019, Cancer letters.

[263]  Bixiang Zhang,et al.  FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21 , 2019, Journal of Experimental & Clinical Cancer Research.

[264]  I. Taylor,et al.  ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer. , 2019, Journal of Clinical Oncology.

[265]  J. Flanagan,et al.  Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer , 2019, Poster Session Abstracts.

[266]  N. Leslie,et al.  Mechanisms of PTEN loss in cancer: It's all about diversity. , 2019, Seminars in cancer biology.

[267]  A. Avan,et al.  Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives. , 2019, Biochimie.

[268]  F. Cossu,et al.  Targeting the BIR Domains of Inhibitor of Apoptosis (IAP) Proteins in Cancer Treatment , 2019, Computational and structural biotechnology journal.

[269]  Mengqing Li,et al.  LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway , 2019, Theranostics.

[270]  K. Carraway,et al.  Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer. , 2019, Endocrine-related cancer.

[271]  J. Schellens,et al.  A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours , 2018, British Journal of Cancer.

[272]  Yang Liu,et al.  Upregulation of USP11 promotes epithelial‑to‑mesenchymal transition by deubiquitinating Snail in ovarian cancer. , 2018, Oncology reports.

[273]  Z. Hua,et al.  Apoptosis and apoptotic body: disease message and therapeutic target potentials , 2018, Bioscience reports.

[274]  Frederic A. Fellouse,et al.  Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response , 2018, The Journal of Biological Chemistry.

[275]  J. L. Ding,et al.  Ubiquitination and SUMOylation in the chronic inflammatory tumor microenvironment. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[276]  Yuli Jin,et al.  USP10 promotes proliferation and migration and inhibits apoptosis of endometrial stromal cells in endometriosis through activating the Raf-1/MEK/ERK pathway. , 2018, American journal of physiology. Cell physiology.

[277]  Jiandie D. Lin,et al.  Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN , 2018, Nature Communications.

[278]  Wei Yang,et al.  FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells , 2018, Nature.

[279]  S. Monaco,et al.  Discovery of Small Molecule WWP2 Ubiquitin Ligase Inhibitors. , 2018, Chemistry.

[280]  Guowang Xu,et al.  USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma. , 2018, Cancer letters.

[281]  D. Alexandraki,et al.  The pleiotropic effects of the glutamate dehydrogenase (GDH) pathway in Saccharomyces cerevisiae , 2018, Microbial Cell Factories.

[282]  Antonio García de Herreros,et al.  TGFβ-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1. , 2018, Cancer research.

[283]  S. Qiu,et al.  BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways , 2018, Cell Death & Disease.

[284]  Radhika Mathur.  ARID1A loss in cancer: Towards a mechanistic understanding , 2018, Pharmacology & therapeutics.

[285]  Ji-Joon Song,et al.  ANKRD9 is associated with tumor suppression as a substrate receptor subunit of ubiquitin ligase. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[286]  Michael C. Ostrowski,et al.  Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth , 2018, Life Science Alliance.

[287]  Yan-bin Zhao,et al.  USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma. , 2018, Cancer letters.

[288]  Roman A. Zubarev,et al.  The deubiquitinase inhibitor b‐AP15 induces strong proteotoxic stress and mitochondrial damage , 2018, Biochemical pharmacology.

[289]  Wenyi Wei,et al.  SCFFBW7-mediated degradation of Brg1 suppresses gastric cancer metastasis , 2018, Nature Communications.

[290]  Lin He,et al.  Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis , 2018, Cell Research.

[291]  H. Yi,et al.  A novel SMAC mimetic APG‐1387 exhibits dual antitumor effect on HBV‐positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti‐tumor immunity , 2018, Biochemical pharmacology.

[292]  M. Yan,et al.  High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[293]  Zhou Aiping,et al.  Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin‐specific peptidase 9, X‐linked in oral squamous cell carcinoma , 2018, Cancer medicine.

[294]  Da-Qiang Li,et al.  FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression. , 2018, Cancer research.

[295]  P. Sorensen,et al.  Insulin-like growth factor 1 receptor stabilizes the ETV6–NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation , 2018, The Journal of Biological Chemistry.

[296]  P. Pandolfi,et al.  The functions and regulation of the PTEN tumour suppressor: new modes and prospects , 2018, Nature Reviews Molecular Cell Biology.

[297]  D. Faller,et al.  Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors , 2018, Investigational new drugs.

[298]  Xinxiang Li,et al.  FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1α/CEACAM5 functional axis , 2018, International journal of biological sciences.

[299]  Yuntao Guo,et al.  Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway , 2018, Theranostics.

[300]  John T. Chang,et al.  USP11 Enhances TGFβ-Induced Epithelial–Mesenchymal Plasticity and Human Breast Cancer Metastasis , 2018, Molecular Cancer Research.

[301]  E. Prochownik,et al.  The deubiquitinase USP21 stabilizes MEK2 to promote tumor growth , 2018, Cell Death & Disease.

[302]  Wei Xiao,et al.  Ube2s stabilizes β-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development , 2018, Cell Death & Disease.

[303]  J. Xiong,et al.  FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein. , 2018, Cancer letters.

[304]  G. Courtois,et al.  The Many Roles of Ubiquitin in NF-κB Signaling , 2018, Biomedicines.

[305]  Hui Wu,et al.  USP10 inhibits lung cancer cell growth and invasion by upregulating PTEN , 2018, Molecular and Cellular Biochemistry.

[306]  D. Faller,et al.  Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. , 2018, Blood.

[307]  J. Li,et al.  TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways , 2018, Cell Death & Disease.

[308]  J. Zhi,et al.  Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML , 2018, Cancer Chemotherapy and Pharmacology.

[309]  C. Di Sano,et al.  Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells , 2018, Cell Death & Disease.

[310]  H. Oshiumi,et al.  Regulation of RIG-I Activation by K63-Linked Polyubiquitination , 2018, Front. Immunol..

[311]  D. Sterner,et al.  USP7-Specific Inhibitors Target and Modify the Enzyme's Active Site via Distinct Chemical Mechanisms. , 2017, Cell chemical biology.

[312]  K. Anderson,et al.  Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. , 2017, Cell chemical biology.

[313]  N. Kumari,et al.  The roles of ubiquitin modifying enzymes in neoplastic disease. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[314]  M. Blasco,et al.  Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts. , 2017, Cancer cell.

[315]  A. Ciechanover,et al.  The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy. , 2017, Trends in biochemical sciences.

[316]  M. Gyrd-Hansen,et al.  The Met1-Linked Ubiquitin Machinery: Emerging Themes of (De)regulation. , 2017, Molecular cell.

[317]  Elizabeth C. Townsend,et al.  Molecular basis of USP7 inhibition by selective small-molecule inhibitors , 2017, Nature.

[318]  Stephen P. Jackson,et al.  Deubiquitylating enzymes and drug discovery: emerging opportunities , 2017, Nature Reviews Drug Discovery.

[319]  S. Park,et al.  A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1 , 2017, Nature Cell Biology.

[320]  Jun Zhou,et al.  CYLD Deubiquitinates Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 Contributing to Adventitial Remodeling , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[321]  Patrycja Czerwińska,et al.  The complexity of TRIM28 contribution to cancer , 2017, Journal of Biomedical Science.

[322]  Allyson E. Koyen,et al.  SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. , 2017, Cell reports.

[323]  Liguo Wang,et al.  Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction. , 2017, Cancer research.

[324]  D. Baker,et al.  Senescent cells: an emerging target for diseases of ageing , 2017, Nature Reviews Drug Discovery.

[325]  J. Huse,et al.  A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors , 2017, Pediatric blood & cancer.

[326]  S. Wang,et al.  JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells , 2017, Oncogenesis.

[327]  Shenghui He,et al.  Senescence in Health and Disease , 2017, Cell.

[328]  Mengqing Li,et al.  Overexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma , 2017, Thoracic cancer.

[329]  M. Shekhar,et al.  Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs , 2017, The Journal of Biological Chemistry.

[330]  E. White,et al.  Autophagy and Tumor Metabolism. , 2017, Cell metabolism.

[331]  J. Schellens,et al.  A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. , 2017, European journal of cancer.

[332]  D. Green,et al.  Caspase‐8: regulating life and death , 2017, Immunological reviews.

[333]  S. Roy,et al.  Microbes and Cancer. , 2017, Annual review of immunology.

[334]  T. Tan,et al.  USP26 regulates TGF‐β signaling by deubiquitinating and stabilizing SMAD7 , 2017, EMBO reports.

[335]  Liu Liu,et al.  Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development , 2017, Journal of medicinal chemistry.

[336]  Yan Ding,et al.  FBX8 is a metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in colorectal carcinoma. , 2017, Cancer letters.

[337]  C. Lima,et al.  Ubiquitin-like Protein Conjugation: Structures, Chemistry, and Mechanism , 2017, Chemical reviews.

[338]  Guoan Chen,et al.  The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor , 2017, Nature Communications.

[339]  J. Cui,et al.  The F‐box protein FBXL18 promotes glioma progression by promoting K63‐linked ubiquitination of Akt , 2017, FEBS letters.

[340]  Hikaru Tsuchiya,et al.  The emerging complexity of ubiquitin architecture , 2016, Journal of biochemistry.

[341]  G. Hortobagyi,et al.  Deubiquitination and Stabilization of PD-L1 by CSN5. , 2016, Cancer cell.

[342]  F. Feng,et al.  Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis , 2016, Molecular Cancer.

[343]  Jing Zhao,et al.  The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3 , 2016, Nature Communications.

[344]  Y. Asmann,et al.  IAP antagonists induce anti-tumor immunity in multiple myeloma , 2016, Nature Medicine.

[345]  M van Duin,et al.  Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma , 2016, Leukemia.

[346]  A. Schulze,et al.  The multifaceted roles of fatty acid synthesis in cancer , 2016, Nature Reviews Cancer.

[347]  Guang-Biao Zhou,et al.  Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery. , 2016, Pharmacological research.

[348]  N. Mailand,et al.  Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers , 2016, Nature Reviews Molecular Cell Biology.

[349]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[350]  G. Mulligan,et al.  A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma , 2016, Investigational New Drugs.

[351]  M. Hochstrasser,et al.  Recent progress in ubiquitin and ubiquitin-like protein (Ubl) signaling , 2016, Cell Research.

[352]  David Komander,et al.  Ubiquitin modifications , 2016, Cell Research.

[353]  Q. Ye,et al.  MiR-30a-5p/UBE3C axis regulates breast cancer cell proliferation and migration. , 2016, Biochemical and biophysical research communications.

[354]  Tomohiro Watanabe,et al.  Cdx2 Expression and Intestinal Metaplasia Induced by H. pylori Infection of Gastric Cells Is Regulated by NOD1-Mediated Innate Immune Responses. , 2016, Cancer research.

[355]  Qiang Li,et al.  Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer , 2016, Cellular Physiology and Biochemistry.

[356]  E. Kohn,et al.  Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer , 2016, Cancer.

[357]  G. Mulligan,et al.  Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma , 2015, Clinical Cancer Research.

[358]  Zhongmei Zhou,et al.  BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5 , 2015, Nature Communications.

[359]  Jeffrey W. Clark,et al.  Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[360]  Y. S. Shin,et al.  Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer , 2015, Oncotarget.

[361]  J. Ding,et al.  SAG-UPS attenuates proapoptotic SARM and Noxa to confer survival advantage to early hepatocellular carcinoma , 2015, Cell Death Discovery.

[362]  Yuan Zhang,et al.  Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis , 2015, Nature Cell Biology.

[363]  A. Tolcher,et al.  Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors , 2015, Cancer Chemotherapy and Pharmacology.

[364]  S. Hewitt,et al.  PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis , 2015, Nature Communications.

[365]  Yanbao Xiong,et al.  Pellino-1 Positively Regulates Toll-like Receptor (TLR) 2 and TLR4 Signaling and Is Suppressed upon Induction of Endotoxin Tolerance* , 2015, The Journal of Biological Chemistry.

[366]  P. Stärkel,et al.  The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications , 2015, European journal of clinical investigation.

[367]  M. Maris,et al.  Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study , 2015, British journal of haematology.

[368]  Henry W. Long,et al.  CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. , 2015, Cancer research.

[369]  S. Singh,et al.  Over-Expression of Telomere Binding Factors (TRF1 & TRF2) in Renal Cell Carcinoma and Their Inhibition by Using SiRNA Induce Apoptosis, Reduce Cell Proliferation and Migration Invitro , 2015, PloS one.

[370]  S. Linder,et al.  Deubiquitinase inhibition as a cancer therapeutic strategy. , 2015, Pharmacology & therapeutics.

[371]  Yang Jiang,et al.  Ubiquitin-specific peptidase 22 overexpression may promote cancer progression and poor prognosis in human gastric carcinoma. , 2015, Translational research : the journal of laboratory and clinical medicine.

[372]  David C. Smith,et al.  Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study , 2015, Cancer Chemotherapy and Pharmacology.

[373]  H. Chen,et al.  UBE3C Promotes Growth and Metastasis of Renal Cell Carcinoma via Activating Wnt/β-Catenin Pathway , 2015, PloS one.

[374]  Zhong-yu Wang,et al.  Ubiquitin‑specific protease 22‑induced autophagy is correlated with poor prognosis of pancreatic cancer. , 2014, Oncology reports.

[375]  Michele Pagano,et al.  SCF ubiquitin ligase-targeted therapies , 2014, Nature Reviews Drug Discovery.

[376]  H. Pelham,et al.  Peptide and small molecule inhibitors of HECT-type ubiquitin ligases , 2014, Proceedings of the National Academy of Sciences.

[377]  B. Clurman,et al.  Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. , 2014, Cancer cell.

[378]  Shin-Ai Lee,et al.  Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis , 2014, Nature Communications.

[379]  J. Infante,et al.  Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[380]  J. Lingner,et al.  The Shelterin Component TPP1 Is a Binding Partner and Substrate for the Deubiquitinating Enzyme USP7* , 2014, The Journal of Biological Chemistry.

[381]  V. Rotter,et al.  p53: The barrier to cancer stem cell formation , 2014, FEBS letters.

[382]  C. Robson,et al.  Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway , 2014, Oncotarget.

[383]  B. Bartholomew.  Regulating the chromatin landscape: structural and mechanistic perspectives. , 2014, Annual review of biochemistry.

[384]  Q. Gao,et al.  Clinical significance of the ubiquitin ligase UBE3C in hepatocellular carcinoma revealed by exome sequencing , 2014, Hepatology.

[385]  J. Ding,et al.  Ubiquitination by SAG regulates macrophage survival/death and immune response during infection , 2014, Cell Death and Differentiation.

[386]  D. Brander,et al.  Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies , 2014, Leukemia & lymphoma.

[387]  Claudio N. Cavasotto,et al.  High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy , 2014, Cell Death and Disease.

[388]  D. Reece,et al.  Bortezomib in multiple myeloma: systematic review and clinical considerations. , 2014, Current oncology.

[389]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[390]  Z. Ronai,et al.  Roquin-2 Promotes Ubiquitin-Mediated Degradation of ASK1 to Regulate Stress Responses , 2014, Science Signaling.

[391]  M. Satake,et al.  Altered trafficking of mutated growth factor receptors and their associated molecules , 2014, Cellular logistics.

[392]  J. Coulson,et al.  The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells , 2013, Oncogene.

[393]  Weiya Ma,et al.  TRAF4 is a critical molecule for Akt activation in lung cancer. , 2013, Cancer research.

[394]  Peijing Zhang,et al.  Deubiquitination and stabilization of PTEN by USP13 , 2013, Nature Cell Biology.

[395]  S. Maddika,et al.  WD Repeat Protein WDR48 in Complex with Deubiquitinase USP12 Suppresses Akt-dependent Cell Survival Signaling by Stabilizing PH Domain Leucine-rich Repeat Protein Phosphatase 1 (PHLPP1)* , 2013, The Journal of Biological Chemistry.

[396]  J. Dou,et al.  USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis , 2013, Cell Death and Disease.

[397]  Dongmin Gu,et al.  The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1 , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[398]  Robert V Farese,et al.  Cellular fatty acid metabolism and cancer. , 2013, Cell metabolism.

[399]  J. G. Teodoro,et al.  BimEL is phosphorylated at mitosis by Aurora A and targeted for degradation by βTrCP1 , 2013, Cell Death and Differentiation.

[400]  M. Hung,et al.  Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression , 2013, Cell.

[401]  H. Yokosawa,et al.  Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor. , 2013, Bioorganic & medicinal chemistry letters.

[402]  A. Bode,et al.  USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer , 2013, Clinical Cancer Research.

[403]  Qiang Li,et al.  Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-Catenin , 2013, International journal of molecular sciences.

[404]  Changjiang Jin,et al.  The F-box protein β-TrCP promotes ubiquitination of TRF1 and regulates the ALT-associated PML bodies formation in U2OS cells. , 2013, Biochemical and biophysical research communications.

[405]  W. Lam,et al.  The detection and implication of genome instability in cancer , 2013, Cancer and Metastasis Reviews.

[406]  C. Perez-stable,et al.  Betulinic Acid Selectively Increases Protein Degradation and Enhances Prostate Cancer-Specific Apoptosis: Possible Role for Inhibition of Deubiquitinase Activity , 2013, PloS one.

[407]  Shang Li,et al.  The role of telomere biology in cancer. , 2013, Annual review of pathology.

[408]  M. Pagano,et al.  Specific small molecule inhibitors of Skp2-mediated p27 degradation. , 2012, Chemistry & biology.

[409]  Parantu K. Shah,et al.  A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. , 2012, Cancer cell.

[410]  Forest M White,et al.  Molecular Characterization of EGFR and EGFRvIII Signaling Networks in Human Glioblastoma Tumor Xenografts* , 2012, Molecular & Cellular Proteomics.

[411]  J. Grandis,et al.  Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy , 2012, Clinical Cancer Research.

[412]  H. Yokosawa,et al.  Manadosterols A and B, sulfonated sterol dimers inhibiting the Ubc13-Uev1A interaction, isolated from the marine sponge Lissodendryx fibrosa. , 2012, Journal of natural products.

[413]  N. Senzer,et al.  Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[414]  Jeff Porter,et al.  USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor , 2012, Nature Cell Biology.

[415]  M. Rapé,et al.  The ubiquitin code. , 2012, Annual review of biochemistry.

[416]  J. Hazle,et al.  The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis , 2012, Cell.

[417]  E. Choi,et al.  Ring Finger Protein 149 Is an E3 Ubiquitin Ligase Active on Wild-type v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)* , 2012, The Journal of Biological Chemistry.

[418]  K. Iwai,et al.  Analysis of Nuclear Factor-κB (NF-κB) Essential Modulator (NEMO) Binding to Linear and Lysine-linked Ubiquitin Chains and Its Role in the Activation of NF-κB* , 2012, The Journal of Biological Chemistry.

[419]  P. Pandolfi,et al.  The functions and regulation of the PTEN tumour suppressor , 2012, Nature Reviews Molecular Cell Biology.

[420]  V. Battaglia,et al.  Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. , 2012, Chemistry & biology.

[421]  Zhang Zhiqiang,et al.  USP1 regulates AKT phosphorylation by modulating the stability of PHLPP1 in lung cancer cells , 2012, Journal of Cancer Research and Clinical Oncology.

[422]  Su-Jae Lee,et al.  Akt is negatively regulated by the MULAN E3 ligase , 2012, Cell Research.

[423]  J. Baselga,et al.  USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma , 2012, Nature Medicine.

[424]  Wei Wang,et al.  The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer , 2012, Oncogene.

[425]  B. Sarcevic,et al.  Protein monoubiquitination and polyubiquitination generate structural diversity to control distinct biological processes , 2012, IUBMB life.

[426]  K. Vousden,et al.  Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl , 2012, Nature Structural &Molecular Biology.

[427]  G. Mills,et al.  Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression , 2011, Oncogene.

[428]  Cyrus Chargari,et al.  Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. , 2011, Cancer letters.

[429]  Yu Deng,et al.  The E3 ubiquitin ligase Rnf8 stabilizes Tpp1 to promote telomere end protection , 2011, Nature Structural &Molecular Biology.

[430]  Mårten Fryknäs,et al.  Inhibition of proteasome deubiquitinating activity as a new cancer therapy , 2011, Nature Medicine.

[431]  G. Dianov,et al.  Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. , 2011, Chemistry & biology.

[432]  Shou-Dong Lee,et al.  Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase. , 2011, Cellular signalling.

[433]  Clare L. Bennett,et al.  PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells , 2011, EMBO molecular medicine.

[434]  Mike Tyers,et al.  An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme , 2011, Cell.

[435]  Cha Soon Kim,et al.  Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2. , 2011, European journal of cell biology.

[436]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[437]  P. Richardson,et al.  A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. , 2010, Blood.

[438]  C. Harris,et al.  Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence , 2010, Nature Cell Biology.

[439]  P. Cohen,et al.  Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases? , 2010, Cell.

[440]  N. Donato,et al.  Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. , 2010, Cancer research.

[441]  Balazs Halmos,et al.  EGFR-mutated lung cancer: a paradigm of molecular oncology , 2010, Oncotarget.

[442]  A. Zhu,et al.  The role of signaling pathways in the development and treatment of hepatocellular carcinoma , 2010, Oncogene.

[443]  X. Shen,et al.  The potential role of ubiquitin c-terminal hydrolases in oncogenesis. , 2010, Biochimica et biophysica acta.

[444]  Min Jae Lee,et al.  Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of Usp14 , 2010, Nature.

[445]  M. L. Dechassa,et al.  SWI/SNF has intrinsic nucleosome disassembly activity that is dependent on adjacent nucleosomes. , 2010, Molecular cell.

[446]  H. Herfarth,et al.  The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer , 2010, The Journal of experimental medicine.

[447]  R. Flavell,et al.  Tyrosine phosphorylation of SHIP promotes its proteasomal degradation. , 2010, Experimental hematology.

[448]  R. Youle,et al.  IBRDC2, an IBR‐type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation , 2010, The EMBO journal.

[449]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[450]  J. Cheville,et al.  USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 , 2010, Cell.

[451]  Roger E. McLendon,et al.  Targeting A20 Decreases Glioma Stem Cell Survival and Tumor Growth , 2010, PLoS biology.

[452]  G. Crabtree,et al.  Chromatin remodelling during development , 2010, Nature.

[453]  Yvonne A. Evrard,et al.  Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. , 2009, Molecular cell.

[454]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[455]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[456]  I. Chung,et al.  Ubiquitin Ligase RLIM Modulates Telomere Length Homeostasis through a Proteolysis of TRF1* , 2009, Journal of Biological Chemistry.

[457]  S. Linder,et al.  Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin‐proteasome system , 2009, International journal of cancer.

[458]  H. Yokosawa,et al.  Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis. , 2008, Bioorganic & medicinal chemistry letters.

[459]  T. Ludwig,et al.  Negative Regulation of AKT Activation by BRCA1. , 2008, Cancer research.

[460]  D. Sterner,et al.  Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities , 2008, Protein science : a publication of the Protein Society.

[461]  K. Nakayama,et al.  Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. , 2008, Blood.

[462]  A. Aguilera,et al.  Genome instability: a mechanistic view of its causes and consequences , 2008, Nature Reviews Genetics.

[463]  G. Pond,et al.  A Phase 2 study of perifosine in advanced or metastatic breast cancer , 2008, Breast Cancer Research and Treatment.

[464]  B. A. Ballif,et al.  ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.

[465]  Yongge Zhao,et al.  Tumor Necrosis Factor Receptor 2 Signaling Induces Selective c-IAP1-dependent ASK1 Ubiquitination and Terminates Mitogen-activated Protein Kinase Signaling* , 2007, Journal of Biological Chemistry.

[466]  Mark A. Brown,et al.  Epigenetic aberrations and cancer , 2006, Molecular Cancer.

[467]  C. Brancolini,et al.  Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. , 2006, Cancer research.

[468]  Gráinne Barkess.  Chromatin remodeling and genome stability , 2006, Genome Biology.

[469]  W. Wahli,et al.  Transcriptional regulation of metabolism. , 2006, Physiological reviews.

[470]  Xuejun Jiang,et al.  Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. , 2006, Molecular cell.

[471]  A. Matsuda,et al.  Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. , 2006, Oncology reports.

[472]  D. Rodenhiser,et al.  Epigenetics and human disease: translating basic biology into clinical applications , 2006, Canadian Medical Association Journal.

[473]  J. Harper,et al.  The F-box Protein FBX4 Targets PIN2/TRF1 for Ubiquitin-mediated Degradation and Regulates Telomere Maintenance* , 2006, Journal of Biological Chemistry.

[474]  René Bernards,et al.  A Genomic and Functional Inventory of Deubiquitinating Enzymes , 2005, Cell.

[475]  A. Toutain,et al.  Congenital glutamine deficiency with glutamine synthetase mutations. , 2005, The New England journal of medicine.

[476]  T. Lange,et al.  Shelterin: the protein complex that shapes and safeguards human telomeres , 2005 .

[477]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[478]  Michael A. Koldobskiy,et al.  Chemical genetic control of protein levels: selective in vivo targeted degradation. , 2004, Journal of the American Chemical Society.

[479]  K. Anderson,et al.  Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[480]  Peter T Lansbury,et al.  Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. , 2003, Chemistry & biology.

[481]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[482]  T Takahashi,et al.  ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis , 2001, EMBO reports.

[483]  Catherine G. Takizawa,et al.  Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. , 2000, Current opinion in cell biology.

[484]  D. Dean,et al.  Chromatin remodeling and transcriptional regulation. , 1999, Journal of the National Cancer Institute.

[485]  M. Peter,et al.  Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factors by Betulinic Acid* , 1998, The Journal of Biological Chemistry.

[486]  N. Hayashi,et al.  Activation of mitogen‐activated protein kinases/extracellular signal‐regulated kinases in human hepatocellular carcinoma , 1998, Hepatology.

[487]  L. S. Cram,et al.  A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[488]  E. Montoya,et al.  Toxohormone-like Factor from Microorganisms with Impaired Respiration , 1961, Science.

[489]  Xi Wang,et al.  Ubiquitin specific peptidase 38 promotes the progression of gastric cancer through upregulation of fatty acid synthase. , 2022, American journal of cancer research.

[490]  Zhi-wei Wang,et al.  USP7 stabilizes EZH2 and enhances cancer malignant progression. , 2020, American journal of cancer research.

[491]  Tianzhi Huang,et al.  Autophagy and Hallmarks of Cancer. , 2018, Critical reviews in oncogenesis.

[492]  D. Nam,et al.  USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance. , 2016, Neuro-oncology.

[493]  Zhiwei Wang,et al.  Targeting the ubiquitin pathway for cancer treatment. , 2015, Biochimica et biophysica acta.

[494]  P. Richardson,et al.  A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. , 2014, Blood.

[495]  A. Ciliberto,et al.  Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. , 2012, Physiological reviews.

[496]  R. Ramesh,et al.  MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin–proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity , 2008, Cancer Gene Therapy.

[497]  T. de Lange,et al.  Shelterin: the protein complex that shapes and safeguards human telomeres. , 2005, Genes & development.

[498]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[499]  Alexander Varshavsky,et al.  The ubiquitin system. , 1998, Annual review of biochemistry.

[500]  P. Chambon,et al.  Nucleosome structure. , 1978, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.